Skip to main content

Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis

Written by Customer Service on . Posted in Public Companies.

UNIONDALE, N.Y., Sept. 08, 2021 (GLOBE NEWSWIRE) — Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, announced today it is scheduled to host a virtual research and development day focused on its product candidate ANG-3070, a novel, highly selective, and orally-bioavailable small molecule tyrosine kinase receptor inhibitor in clinical development for the treatment of fibrotic diseases, including those in the kidney and lung, at 10:00am EDT on Monday, September 20th.

The event will feature presentations by two medical experts, including Joseph V. Bonventre, M.D., Ph.D., Harvard Medical School, who will discuss the current treatment landscape and unmet medical needs of patients with kidney fibrosis, and Gregory P. Downey, M.D., National Jewish Health, who will discuss the current treatment landscape and unmet medical needs of patients with lung fibrosis.

With this context, Angion’s Chief Medical Officer, Dr. John Neylan, and Dr. Shakil Aslam, its VP of Early Clinical Development and Translational Medicine, will discuss the pre-clinical and clinical rationale for the development of ANG-3070, which is currently being investigated in a Phase 2 study in patients with primary proteinuric kidney disease.

A live Q&A will follow the presentations.

To register for the R&D Day, please click here.

Invited Medical Experts
Dr. Joseph V. Bonventre is the Samuel A. Levine Professor of Medicine at Harvard Medical School. He is Chief of the Renal Unit and Chief of the Engineering in Medicine Division at Brigham and Women’s Hospital, Director of Health Sciences and Technology at Massachusetts General Hospital, and professor at the Harvard-MIT Health Sciences and Technology, Brigham and Women’s Hospital. Dr. Bonventre is a member of the Kidney Cancer Program at the Dana-Farber/Harvard Cancer Center.

Dr. Bonventre has authored more than 360 original publications and 150 invited chapters and reviews, has received two MERIT awards from the National Institutes of Diabetes and Digestive and Kidney Disorders (NIDDK), and his work has been cited more than 52,000 times with an h-index of 117. He has been elected to the American Society of Clinical Investigation, the Association of American Physicians, and the American Institute for Medical and Biological Engineering.
        
Dr. Gregory P. Downey is a Professor of Medicine, Pediatrics, and Biomedical Research and the Executive Vice President for Academic Affairs at National Jewish Health in Denver, CO. Dr. Downey is also a Professor of Medicine and Immunology and Microbiology and the Associate Dean of the School of Medicine at the University of Colorado, Denver.

Dr. Downey’s primary research is focused on the mechanisms of lung injury, repair, and fibrosis and he is an internationally recognized leader in this field. He has authored over 240 peer-reviewed publications, reviews, and book chapters and his work has been cited more than 17,000 times. He is the President-Elect of the American Thoracic Society.

Angion Biomedica Corp.
Angion is committed to transforming the treatment paradigm for patients suffering from acute organ injuries and fibrotic diseases for which there are no approved medicines or where existing approved medicines have limitations. Angion’s lead product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic currently being evaluated in a Phase 3 registration trial for delayed graft function in patients undergoing deceased donor kidney transplantation and a Phase 2 trial in cardiac-surgery associated acute kidney injury. Angion is scheduled to begin a Phase 2 trial evaluating ANG-3070, an oral tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in patients with primary proteinuric kidney diseases. Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor. For more information, please visit www.angion.com.

Investor Contact:
Daniel Ferry
LifeSci Advisors        
daniel@lifesciadvisors.com
P: 617-430-7576

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.